Analysis on Selected Stocks of Pharmaceutical Companies in NSE, India

This study examines the financial performance of selected pharmaceutical stocks listed on the National Stock Exchange (NSE) of India, a key sector driving the country’s economic growth and healthcare innovation. By employing quantitative analysis, the research evaluates metrics such as stock performance, volatility, and investment potential among five major companies: Lupin, Sun Pharmaceuticals, Cipla Ltd, Aurobindo Pharma, and Dr. Reddy’s Laboratories. Findings reveal significant variations in performance, with Lupin leading in mean returns and risk-adjusted metrics, while Dr. Reddy’s shows underperformance. This article reviews relevant literature, identifies research gaps, employs a quantitative analysis method, and presents findings on stock performance, volatility, and investment potential. The results indicate varying performance metrics across selected companies, influenced by market dynamics and external factors. This analysis contributes to a deeper understanding of the pharmaceutical stock landscape in India and provides insights for investors and policymakers.